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Purpose: To investigate whether implantation of a glaucoma shunt device leads to inappropriate accumulation of plasma
derived proteins in the aqueous humor.
Methods:  Aqueous  humor  samples  were  collected  from  11  patients  (study  group)  with  a  glaucoma  shunt  device
undergoing either cataract surgery or a corneal transplant and 11 patients (control) with senile cataract undergoing routine
cataract extraction. Of the study group, 9 had an Ahmed valve implant and 2 eyes had a Baerveldt implant. Tryptic digests
of the mixture of proteins in aqueous humor (AH) were analyzed using Liquid Chromatography/Mass Spectrometry (LC-
MS/MS). Proteins were identified with high confidence using stringent criteria and compared quantitatively using a label-
free platform (IdentiQuantXLTM).
Results: We identified 135 proteins in the albumin-depleted fraction in both the study and control group AH. Using
stringent criteria, 13 proteins were detected at a significantly higher level compared to controls. These proteins are known
to play a role in oxidative stress, apoptosis, inflammation and/or immunity and include gelsolin (p=0.00005), plasminogen
(p=0.00009), angiotensinogen (p=0.0001), apolipoprotein A-II (p=0.0002), beta-2-microglobulin (p=0.0002), dickkopf-3
(DKK-3;  p=0.0002),  pigment  epithelium-derived  factor  (p=0.0002),  RIG-like  7–1  (p=0.0002),  afamin  (p=0.0003),
fibronectin 1 (FN1; p=0.0003), apolipoprotein A-I (p=0.0004), activated complement C4 protein (C4a; p=0.0004) and
prothrombin (p=0.0004). Many of the identified proteins were novel proteins that have not been associated with glaucoma
in prior studies. All but C4a (complement C4 is a plasma protein but not in an activated form) are known plasma proteins
and the elevated levels of these proteins in the aqueous humor suggests a breach in the blood-aqueous barrier with passive
influx into the anterior chamber of the eye.
Conclusions: The presence of these proteins in the aqueous humor suggests that glaucoma shunt device causes either a
breach in blood-aqueous barrier or chronic trauma, increasing influx of oxidative, apoptotic and inflammatory proteins
that could potentially cause corneal endothelial damage.
Glaucoma  is  an  optic  neuropathy  characterized  by
progressive loss of retinal ganglion cells that lead to structural
changes at the optic nerve head and functional visual loss. It
is often, but not always, associated with increased intra-ocular
pressure (IOP). According to the World Health Organization,
it is the second leading cause of blindness in the world and
accounts  for  9%–12%  of  cases  of  blindness  in  the  US.
Management strategies include medical therapy usually in the
form of topical anti-glaucoma medications to lower IOP. If
IOP is resistant to medical therapy and/or there is progressive
optic nerve damage, surgery is considered, usually in the form
of trabeculectomy or a glaucoma shunt device.
Glaucoma  has  long  been  recognized  as  an  important
factor  influencing  corneal  graft  survival  [1-5].  In  our
published  series  of  over  4,000  full  thickness  penetrating
keratoplasties, we identified pre-existing glaucoma as a risk
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factor for graft failure and other authors have reported similar
outcomes [2,6,7]. High intra-ocular pressure (IOP) is not only
detrimental to optic nerve function, it can also lead to corneal
endothelial  cell  attrition.  Glaucoma  filtration  surgery,
although essential for preservation of visual function, has also
been known to affect corneal graft survival adversely with
several series citing poor longer-term graft survival especially
in eyes with a glaucoma shunt device [8-10]. More recently,
in  eyes  undergoing  endothelial  keratoplasty,  glaucoma
filtration surgery also had a significantly adverse effect on
graft survival [11].
The mechanisms of corneal endothelial damage in eyes
with  a  glaucoma  shunt  device  are  not  fully  understood.
Glaucoma shunt devices can damage the corneal endothelium
by mechanical means or by permitting retrograde entrance of
inflammatory  cells  into  the  anterior  chamber  [12-15].  In
addition, glaucoma shunt devices disrupt the blood–aqueous
barrier and this could further increase influx of inflammatory
mediators  that  could  potentially  cause  corneal  endothelial
damage.
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1891Proteomics  is  one  of  the  emerging  techniques  for
biomarker discovery. Aqueous humor (AH) is the biologic
fluid in the eye that has the task of protecting and supplying
nutrition to the cornea, lens and trabecular meshwork (TM).
A balance between production and drainage of AH is critical
to maintaining normal IOP. The protein composition of AH
has  been  shown  to  change  dramatically  in  various  ocular
conditions such as corneal graft rejection [16], myopia [17],
corneal dystrophies [18-20], and glaucoma [21-24]. Although
the exact pathogenesis of glaucoma remains unclear, it is
likely that alterations in the AH protein composition trigger
signaling molecules that could modify the TM, increasing
resistance to outflow and hence glaucoma [25,26].
With this background in mind, we decided to explore the
AH proteomics in eyes with a pre-existing glaucoma shunt
device to characterize the proteins that could potentially serve
as biomarkers for not only glaucoma but also for corneal
endothelial damage. The results of this study could potentially
influence therapeutic strategies designed to improve longer-
term graft survival in these high-risk eyes.
METHODS
Sample  collection:  Patients  were  selected  and  samples
collected as previously described [27]. Briefly, study subjects
were either patients scheduled to undergo routine cataract
surgery (controls) or patients with previous glaucoma shunt
device scheduled to undergo corneal transplant or cataract
surgery  at  a  tertiary  referral  center,  Price  Vision  Group
(Indianapolis, IN). Exclusion criteria were as follows: history
of conjunctivitis or any ocular infection within the previous 3
months  and  ongoing  intraocular  inflammation.  An
independent review board (IRB) approved the study and all
subjects signed a written Informed Consent document. Before
surgery,  the  patient's  eye  was  anesthetized  topically  with
proparacaine.  A  stab  incision  was  made  in  the  peripheral
cornea,  and  0.1  to  0.2  ml  of  anterior  chamber  fluid  was
aspirated using a 30-gauge needle. AH samples were stored
frozen in liquid nitrogen until analysis. Any sample suspected
of  being  contaminated  with  blood  or  iris  pigment  was
discarded.  Samples  from  22  subjects  were  analyzed  (11
cataract patients and 11 patients with glaucoma shunt device)
as shown in Table 1.
Materials:  Acetonitrile  and  ammonium  bicarbonate  were
purchased  from  Fisher  Scientific  (Fair  Lawn,  NJ).
Dithiothreitol (DTT) and iodoacetamide (IAA) were obtained
from  Bio-Rad  Laboratories  (Hercules,  CA).  Trypsin  was
purchased  from  Promega  (Madison,  WI).  ProteoPrep
immunoaffinity depletion kit was purchased from Sigma (St.
TABLE 1. CLINICAL DATA ON STUDY PATIENTS AND NORMAL CONTROLS.
Age Sex Type of surgery during aqueous humor tap
Study patients
69 Female Cataract
56 Male Corneal transplant
31 Male Cataract
56 Male Corneal transplant
23 Male Corneal transplant
74 Male Corneal transplant
45 Male Cataract
90 Female Corneal transplant
49 Male Corneal transplant
89 Male Corneal transplant
71 Female Repeat glaucoma shunt
Normal controls
52 Male Cataract
73 Male Cataract
76 Female Cataract
72 Male Cataract
70 Male Cataract
73 Male Cataract
63 Female Cataract
43 Female Cataract
60 Female Cataract
66 Female Cataract
56 Female Cataract
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1892Louis,  MO).  The  following  sample  preparation  and  mass
spectrometric  analyses  were  performed  at  MetaCyt
Biochemical Analysis Center (Bloomington, IN).
Depletion and protein assay: Depletion of albumin and IgG
was  performed  using  the  ProteoPrep  immunoaffinity
depletion kit (Sigma) as described in instruction manual with
some modification. As the depletion kit is designed for plasma
samples and the protein content in AH is significantly lower,
preliminary studies were performed to develop a protocol for
optimal AH depletion, which resulted in enhanced protein
identification  (data  not  shown).  Briefly,  an  estimation  of
material to be used to deplete albumin and IgG from AH was
made using a BCA protein assay and quantification of albumin
and IgG in AH samples relative to plasma assuming total
protein content of 80 µg/µl and 75% albumin and IgG in
plasma. The estimated amount of material by weight was
measured from the ProteoPrep immunoaffinity column and
transferred  to  an  empty  spin  column,  and  depletion  was
performed as described in the instruction manual.
Trypsin digestion: Protein samples were subjected to tryptic
digestion  before  analysis  as  follows:  after  thermal
denaturation at 95 °C for 5 min, samples were reduced through
the addition of DTT to a final concentration of 5 mM and
incubated at 60 °C for 45 min. Alkylation was then followed
by an addition of IAA to a final concentration of 20 mM for
45 min in the dark at room temperature. A second aliquot of
DTT was then added, increasing the final concentration of
DTT to about 10 mM. The samples were then incubated at
room  temperature  for  30  min  to  quench  the  alkylation
reaction. Next, trypsin was added (1:30 w/w) and microwave-
assisted enzymatic digestion was performed at 45 °C for 15
min at the power of 50 W. Finally enzymatic digestion was
quenched through the addition of 0.5 µl of neat formic acid.
Instrumentation:  Liquid  chromatography  tandem  mass
spectrometry  (LC-MS/MS)  analyses  of  the  tryptic  digests
were  performed  using  a  Dionex  3000  Ultimate  nano-LC
system  (Dionex,  Sunnyvale,  CA)  interfaced  to  an  LTQ
Orbitrap hybrid mass spectrometer (Thermo Scientific, San
Jose,  CA).  Prior  to  separation,  a  4-µl  aliquot  of  trypsin
digestion  (1  µg  protein  equivalent)  was  loaded  onto  a
PepMap300 C18 cartridge (5 µm, 300 Å; Dionex) and eluted
through the analytical column (150 mm×100 µm i.d, 200 Å
pores)  packed  with  C18  magic  (Michrom  Bioresources,
Auburn, CA). Peptides originating from protein tryptic digests
were separated using a reversed-phase gradient from 10%–
55% B, 99.9% acetonitrile with 0.1% formic acid over 50 min
for proteins isolated from the aqueous humor, at 500 nl/min
flow rate and passed through an ADVANCE ionization source
(Michrom  Bioresources).  The  mass  spectrometer  was
operated  in  an  automated  data-dependent  mode  that  was
switching between MS scan and CID-MS. In this mode, eluted
LC products undergo an initial full-spectrum MS scan from
m/z 300 to 2,000 in the Orbitrap at 15,000 mass resolutions,
and  subsequently  CID-MS  (at  35%  normalized  collision
energy) was performed in the ion trap. The precursor ion was
isolated using the data-dependent acquisition mode with a 2
m/z isolation width to select automatically and sequentially
five most intense ions (starting with the most intense) from
the survey scan. The total cycle (6 scans) was continuously
repeated  for  the  entire  LC-MS  run  under  data-dependent
conditions with dynamic exclusion set to 60 s. Performing MS
scanning  in  the  Orbitrap  offers  high  mass  accuracy  and
accurate charge state assignment of the selected precursor
ions.
Protein identification and label-free quantification:
Peptide and protein identification—The acquired data
were searched against the International Protein Index (IPI)
human database (ipi.HUMAN.v3.69.fasta) using SEQUEST
(v. Twenty-eight rev. 12) algorithms in Bioworks (v. 3.3).
General parameters were set to: peptide tolerance 2.0 amu,
fragment ion tolerance 1.0 amu, enzyme limits set as “fully
enzymatic - cleaves at both ends,” and missed cleavage sites
set at 2. The searched peptides and proteins were validated by
PeptideProphet [28] and ProteinProphet [29] in the Trans-
Proteomic  Pipeline  (TPP,  v.  3.3.0).  Only  proteins  with
probability ≥0.9000 and peptides with probability ≥0.8000
were reported.
Protein  quantification—Protein  quantification  was
performed  using  an  in-house  software  package,
IdentiQuantXLTM.  The  retention  time  of  peptide  for  its
intensity extraction was performed with an experiment-based
algorithm  RetentionTimeXLTM.  The  intensity  of  validated
peptide  was  extracted  and  the  protein  quantification  was
calculated from peptide intensity.
Statistical analysis: The relative quantity of each protein was
determined in each individual AH sample, and the results for
the two groups  were compared  using  the Student’s t-test.
A p-value <0.05 was considered to be statistically significant 
but then post-hoc  adjustment of the  p-value was performed
using Holm-Sidak test to correct for multiple comparisons.
RESULTS
We performed label-free quantitative mass spectrometry on
AH samples derived from patients with and without prior
glaucoma  shunt  surgery.  AH  samples  were  depleted  of
interfering abundant proteins such as albumin before LC-
MSMS was used for protein identification and quantification.
We identified 135 proteins in the albumin-depleted fraction
(Table 2) with high confidence in the study as well as control
group AH. After using stringent detection criteria, the AH in
eyes with a prior glaucoma shunt device showed significantly
increased levels of 13 proteins as shown in bold in Table 2.
These  proteins  were  pro-inflammatory  (plasminogen
[p=0.00009],  angiotensinogen  [p=0.0001],  prothrombin
[p=0.0004] and C4a protein [p=0.0004]); anti-oxidative/anti-
apoptotic (gelsolin [p=0.00005], afamin [p=0.0003] pigment
epithelium-derived factor [PEDF; p=0.0002], and dickkopf-3
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[apo  A-1;  p=0.0004],  and  apolipoprotein  A-II  [apo  A-II;
p=0.0002]); or other roles (fibronectin 1 [FN1; p=0.0003],
RIG-like  7–1  [p=0.0002],  and  beta-2-microglobulin
[p=0.0002]). The percent of protein sequence covered by the
peptides identified with high confidence is listed for each
protein along with the number of unique sequences as well as
the  fold-change  compared  to  the  protein  level  in  control
patients.
DISCUSSION
This  study  highlights  for  the  first  time  the  differential
expression of AH proteins in eyes with a glaucoma shunt
device compared to normal controls. Many of the identified
proteins except fibronectin [30] and PEDF [31] are novel
proteins that to our knowledge have not been detected in the
AH of glaucoma patients. Interestingly, all of the identified
proteins except C4a are known plasma proteins and increased
expression in the AH suggests a breach in the blood aqueous
barrier caused by a glaucoma drainage device. AH proteome
changes identified in this study may not only help elucidate
glaucoma pathogenesis but also shed light on the possible
mechanisms that result in corneal endothelial damage and
hence  accelerated  corneal  transplant  failure  in  eyes  with
glaucoma surgery.
We found a significant upregulation of complement C4a
(fold  change,  5;  p=0.0004),  an  activated  fragment  of
complement component C4. Complement activation is under
the  tight  control  of  complement  inhibitors;  uncontrolled
complement activation can cause cell lysis and inflammation
while a balanced activation is necessary for clearing tissue
debris and in healing. Imbalance in complement regulation
has also been suggested to contribute to the neurodegenerative
damage  characteristic  of  glaucoma  [32].  Activated
complement in the AH, as seen in this study, could possibly
cause corneal endothelial damage via direct cell lysis and
inflammation.
There  was  evidence  of  enhanced  fibrinolytic  and
coagulative activity in the AH as suggested by differential
expression  of  prothrombin  (fold  change,  2.9;  p=0.0004),
angiotensinogen  (fold  change,  4.4;  p=0.0001)  and
plasminogen (fold change, 6.2; p=0.00005). O’Brien et al.
[33] have reported elevated prothrombin levels in the plasma
of  patients  with  primary  open  angle  glaucoma  and  have
implicated  this  hypercoagulable  state  in  glaucoma
pathophysiology.  Angiotensinogen  is  a  component  of  the
renin-angiotensin  (RAS)  system  and  plays  a  role  in  the
regulation of AH dynamics [34]. Plasminogen is a component
of the plasmin system, and the main physiologic inhibitor of
the  plasmin  system  is  plasminogen  activator  inhibitor-1
(PAI-1). Elevated levels of PAI-1 have been reported in the
AH  of  glaucoma  patients  thus  contributing  to  glaucoma
pathogenesis  by  reducing  proteolysis  of  the  extracellular
matrix in the TM and increasing resistance to outflow [35].
Prothrombin is also recognized as a biomarker of systemic
sepsis and inflammation [36] and elevated levels in the AH
suggest increased inflammation due to a breach in the blood-
aqueous  barrier  caused  by  the  glaucoma  shunt  device.
Increased  inflammation  has  been  shown  to  stimulate
increased  synthesis  of  pro-inflammatory  cytokines  like
interleukin-1  and  tumor  necrosis  factor  by  the  corneal
endothelium [37,38] leading to corneal endothelial damage.
Afamin (fold change, 3.3; p=0.0003) and gelsolin (fold
change, 4.7; p=0.00005) were the 2 extracellular chaperones
found to be differentially expressed in the AH of patients with
glaucoma shunt device compared to normals. Afamin is a
member of the albumin multigene family with vitamin E-
binding properties. It plays a crucial role in protecting against
oxidative damage and displays neuroprotective activity not
only by virtue of binding and transporting vitamin E but also
on its own [39]. Gelsolin is an anti-oxidant and anti-apoptotic
protein that has been implicated as a therapeutic target in
Alzheimer disease since it has been shown to reduce amyloid
load by inhibiting Abeta fibrillization in animal studies [40].
A decreased level of gelsolin has been observed in patients
with sepsis, myocardial infarction and inflammation while an
increased level has been noted in amyloidosis [41,42], so it
could be a secondary response to increased amyloid load The
upregulation  of  these  extracellular  chaperones  is  likely  a
response  to  the  increased  oxidative  stress  in  the  aqueous
secondary to glaucoma. Oxidative stress has been recognized
as  the  main  pathogenic  factor  underlying  open  angle
glaucoma [43-45]. It is likely that this may also contribute to
corneal endothelial damage. Increased expression of these
proteins  may  reflect  the  inability  of  these  extracellular
chaperones  to  completely  inhibit  oxidative  and  apoptotic
damage both in the TM as well as the corneal endothelium.
Pigment epithelium-derived factor (PEDF), a member of
the serpin family of proteins and expressed in all ocular tissues
of the human eye, was significantly upregulated in eyes with
a glaucoma shunt device (fold change, 4.6; p=0.0002). It is
neuroprotective and anti-angiogenic and recently recognized
as  an  endogenous  anti-inflammatory  factor  [46,47].
Significantly reduced levels have been reported in advanced
glaucoma AH compared to normal controls [31]. Additionally
in animal models, PEDF has been shown to protect retinal
ganglion  cells  from  pressure-induced  ischemia  [48].  Our
finding  of  significantly  increased  expression  of  PEDF  is
intriguing and leads us to speculate that perhaps this protein
serves a protective role in the AH.
The function of Dickkopf-3 (Dkk3) is unclear; however,
Jung et al. [49] suggest that it may acts as an anti-apoptotic
molecule by decreasing intracellular levels of reactive oxygen
species. Recently Nakamura et al. [50] have demonstrated that
it may play a cytoprotective role in the retina by reducing
caspase activity and hence protecting against apoptosis. Its
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1897role  in  glaucoma  and  corneal  endothelial  damage  needs
further evaluation.
Increased expression of apolipoprotein A-I (fold change,
6.4; p=0.0004) and A-II (fold change, 18.4; p=0.0002) was
observed in this study. Apo A-1 and – II, by virtue of their
association with high density lipoprotein (HDL), have anti-
inflammatory properties [51]. However, its specific role in
glaucoma  and  corneal  endothelial  damage  is  unclear  and
requires further investigation.
Fibronectin, an extracellular matrix glycoprotein, was
increased sixfold in this study compared to normal controls
(p=0.0003). This suggests disruption of the blood aqueous
barrier that occurs in eyes with a glaucoma shunt device.
Vesaluoma et al. [30] have demonstrated increased expression
of  this  protein  in  eyes  with  pseudoexfoliation  glaucoma.
Increased fibronectin can transform TM cells and decrease the
breakdown of extracellular matrix material, allowing excess
to  accumulate.  This  could  ultimately  reduce  trabecular
outflow and raise IOP.
RIG-like 7–1 constitute a family of pattern recognition
receptors  (PRRs).  They  mediate  the  initial  sensing  of
microbial and endogenous danger-associated molecules that
are released by tissue damage. By activating transcription of
inflammatory genes they are known to control the immediate
innate immune response as well as the subsequent adaptive
immune response [52]. Increased levels of PRR suggests an
alteration in the immunologic milieu of the AH secondary to
a breach in the blood aqueous barrier.
Beta-2 microglobulin is a protein associated with major
histocompatibility complex class I antigens and has value as
a marker for immunologic monitoring with increased levels
associated with renal and cardiac allograft rejection [53,54].
Elevated  levels  as  seen  in  this  study  (fold  change,  5.7;
p=0.0002)  suggest  a  potential  role  for  this  protein  as  a
biomarker of increased immune mediated corneal endothelial
damage in eyes with a glaucoma shunt device.
Based on the protein profile detected in this study we have
hypothesized  the  likely  mechanisms  underlying  corneal
endothelial damage in eyes with a shunt device as well as new
insights into glaucoma pathophysiology. Glaucoma per se
also causes corneal endothelial damage and in the presence of
glaucoma shunt device there is likely to be an exaggerated
stress response leading to corneal endothelial damage and
endothelial failure. This has important implications especially
in  the  setting  of  corneal  transplants.  Corneal  grafts  have
significantly poor long-term survival in the presence of a shunt
device and future work should be targeted at identifying the
specific role for these proteins so that they could potentially
serve as therapeutic targets to improve graft outcomes.
This  study  has  several  strengths  that  need  to  be
highlighted. The AH samples were not pooled but analyzed
individually to determine proteins associated with a shunt
device. We used conservative criteria for determining which
proteins were differentially expressed between groups and
were able to identify highly significant proteins with a large
fold change compared to normals. It has been shown that the
proteomic profile in glaucoma patients can vary depending on
the severity of visual field defects [22]. The study patients had
advanced  glaucoma  and  this  could  partly  explain  the
identification of novel proteins. The limitations of this study
include the small sample size, although it is comparable to
previous studies evaluating AH in eyes with glaucoma [21,
22].  A  useful  control  group  would  have  been  glaucoma
patients without a shunt device who were undergoing intra-
ocular surgery. A proteomic study with glaucoma as a control
group is currently ongoing and should provide more insight
into the pathogenic mechanism of corneal endothelial damage
specific  to  glaucoma  shunt  device.  This  study  reports  on
differential  expression  of  proteins  compared  to  normal
controls but does not provide absolute quantitative data on
protein levels.
Lastly,  the  majority  of  study  patients  had  an  Ahmed
glaucoma shunt, which is a valved implant designed to prevent
retrograde flow of fluid from the filtering bleb into the eye, so
it  would  be  interesting  to  determine  the  mechanism  of
increased inflammation and/or immunologic alterations seen
in these eyes. Future work should be directed at evaluating the
AH proteomic expression in the presence of valved and non-
valved  glaucoma  shunts  to  shed  light  on  the  possible
mechanisms  of  corneal  endothelial  damage  with  different
types of shunts.
Conclusion:  We  demonstrated  significantly  altered
expression of 13 proteins in AH of eyes with a glaucoma shunt
device. Many of these proteins play a role in oxidative and
apoptotic damage. The findings of this study seem to suggest
similar mechanisms underlying both glaucoma and corneal
endothelial  damage.  Future  work  should  be  targeted  at
identifying aqueous proteins that could potentially serve as
markers  for  corneal  endothelial  damage  in  eyes  with
glaucoma shunt device.
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